CCN5

Across TCGA pan-cancer cohorts, CCN5 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CCN5 data layer compared with 23 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CCN5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CCN5 expression acts as an unfavorable survival marker.

PDAC, LUAD, and CCRCC are the cancer types where CCN5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.675	0.867	.003	31	view →
LUAD	OS	Median	II,III,IV	0.477	0.828	.004	20	view →
CCRCC	DFS	Median	II,III,IV	0.295	0.827	.010	9	view →
UCEC	DFS	Quartile	III,IV	0.643	1.000	.043	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CCN5–PDAC (DFS)

Open the PDAC breakdown →